Your U.S. Based Biologics Partner

Expanding biologics production demands scalable infrastructure that balances speed, operational flexibility, and long-term cost efficiency. A newly expanded manufacturing hub in Bayview, Maryland, addresses these critical needs by introducing 16,000 liters of single-use bioreactor capacity, featuring 2,000-liter and 4,000-liter systems designed to deliver significant economies of scale.

Equipped with three segregated value streams and traditional monoclonal antibody processing equipment, the facility supports everything from early cell line development to commercial-scale supply. Single-use technology ensures rapid process adaptation, while comprehensive on-site quality control, specialized testing laboratories, and extensive cold-chain storage safeguard product integrity throughout the lifecycle. This strategic expansion provides closer proximity to North American clients, strengthening supply chain resilience across global operations.

Explore the operational capabilities, equipment highlights, and technical specifications of this state-of-the-art facility to optimize your next manufacturing phase.